Related references
Note: Only part of the references are listed.A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
Profile of veliparib and its potential in the treatment of solid tumors
Lars M. Wagner
ONCOTARGETS AND THERAPY (2015)
Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies
Ahmed Hamed Salem et al.
CLINICAL PHARMACOKINETICS (2014)
Use of In Vitro-In Vivo Correlation to Predict the Pharmacokinetics of Several Products Containing a BCS Class 1 Drug in Extended Release Matrices
Tahseen Mirza et al.
PHARMACEUTICAL RESEARCH (2013)
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
P Jagtap et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Share Paper
